Handelsbanken Fonder Ab Prothena Corp Public LTD CO Transaction History

Handelsbanken Fonder Ab

$25.3 Billion
Q3 2024

A detailed history of Handelsbanken Fonder Ab transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 15,400 shares of PRTA stock, worth $212,674. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,400

Previous 15,400 -0.0%

Holding current value

$212,674

Previous $318,000 18.87%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	BUY	$19.54 - $26.15 $117,240 - $156,900	6,000 Added 63.83%	15,400 $318,000
Q1 2024 May 13, 2024	SELL	$24.75 - $40.66 $1.29 Million - $2.11 Million	-52,000 Reduced 84.69%	9,400 $233,000
Q4 2023 Feb 01, 2024	BUY	$32.31 - $52.32 $80,775 - $130,800	2,500 Added 4.24%	61,400 $2.23 Million
Q2 2023 Aug 02, 2023	BUY	$48.26 - $78.59 $332,994 - $542,271	6,900 Added 13.27%	58,900 $4.02 Million
Q4 2022 Feb 07, 2023	SELL	$52.05 - $65.0 $1.75 Million - $2.19 Million	-33,700 Reduced 39.32%	52,000 $3.13 Million
Q3 2022 Oct 27, 2022	SELL	$25.16 - $60.63 $1.05 Million - $2.53 Million	-41,800 Reduced 32.78%	85,700 $5.2 Million
Q2 2022 Aug 03, 2022	BUY	$22.73 - $39.98 $661,443 - $1.16 Million	29,100 Added 29.57%	127,500 $3.46 Million
Q4 2021 Feb 08, 2022	SELL	$42.11 - $73.26 $475,843 - $827,838	-11,300 Reduced 10.3%	98,400 $4.86 Million
Q3 2021 Nov 10, 2021	BUY	$48.2 - $78.89 $482,000 - $788,900	10,000 Added 10.03%	109,700 $7.81 Million
Q2 2021 Aug 03, 2021	BUY	$21.63 - $57.65 $2.16 Million - $5.75 Million	99,700 New	99,700 $5.13 Million
Q4 2017 Feb 08, 2018	SELL	$35.44 - $63.76 $886,000 - $1.59 Million	-25,000 Closed	0 $0
Q3 2017 Nov 01, 2017	BUY	$53.83 - $67.75 $1.35 Million - $1.69 Million	25,000	25,000 $1.62 Million

Others Institutions Holding PRTA

# of Institutions

184

Shares Held

42.7M

Call Options Held

162K

Put Options Held

102K

View Full List

About PROTHENA CORP PUBLIC LTD CO

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $648M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

More about PRTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

News

Stay updated on Handelsbanken Fonder Ab with notifications on news.

Account

Handelsbanken Fonder Ab Prothena Corp Public LTD CO Transaction History